A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors

Inclusion criteria

• Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
• Patients with unresectable recurrent or metastatic solid tumors;
• There is at least one lesion could be measured;
• An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
• Adequate organ functions as defined;
• Life expectancy ≥3 months.

Exclusion criteria

• Patients with known active central nervous system (CNS) metastases;
• Subjects who had other malignancy in five years before the first dose;
• Patients with tumor-related pain that cannot be controlled as determined;
• Patients with serious cardiovascular and cerebrovascular diseases;
• Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
• Patients with Severe infections;
• History of immunodeficiency;
• History of autoimmune diseases;
• Unresolved CTCAE Grade >1 toxicity attributed to any prior anti-tumor therapy
• Active infection;
• Pregnant or nursing women;
• Known history of serious allergic reactions to the investigational product or its main ingredients.